| Literature DB >> 30156427 |
Mariana Brandão1, Noam Pondé1, Martine Piccart-Gebhart1.
Abstract
The number of breast cancer (BC) cases is growing worldwide, being most frequently diagnosed in the early-setting. Mammaprint™ is a 70-gene-expression signature, originally designed for selecting early BC patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy. Its use as a prognostic biomarker has been extensively validated, both retrospectively and prospectively. However, its value as a predictive tool and as a clinically useful tool remains controversial. This review will describe how the test works, its application in the clinic and its limitations. Cost-effectiveness studies will be summarized. Finally, we will provide a perspective on the use of Mammaprint in the near future, as a valuable tool for personalizing the treatment of early BC patients.Entities:
Keywords: adjuvant chemotherapy; breast neoplasms; gene-expression signatures
Mesh：
Substances：
Year: 2018 PMID： 30156427 DOI： 10.2217/fon-2018-0221
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404